MuLBSTA Score

Not fully reviewed/validated for use with COVID-19 at this time

MuLBSTA Score: Predicts 90‑day mortality risk in patients with viral pneumonia.

Multilobe Infiltrates?
No0Yes+5
Lymphocyte less than ≤0.8x10^9/L?
No0Yes+4
Bacterial Infection?
No0Yes+4
Acute Smoker?
No0Yes+3
Quit Smoking before infxn?
No0Yes+2
HTN?
No0Yes+2
Is patient 60 years or older?
No0Yes+2

Indikationen

Used to stratify 90‑day mortality risk in hospitalized viral pneumonia by incorporating multilobar infiltrates, lymphopenia, bacterial coinfection, smoking status, hypertension, and age ≥60. Helps identify high‑risk patients needing closer monitoring or early escalation. Derived from a 528‑patient cohort with 14.4% mortality, showing AUROC 0.773 and outperforming CURB‑65 1.

Hinweise & Vorsichtsmaßnahmen

Indicates mortality risk in viral pneumonia but has limited validation in COVID‑19 and should not guide decisions alone. Early descriptive data suggested alignment with severe cases 1 [Level III evidence], but multiple systematic reviews show high or unclear risk of bias and unreliable performance across COVID‑19 prognostic tools 2 [Level I evidence]; 3 [Level II evidence]. Use only as supplementary context alongside clinical judgment and established predictors (e.g., age, oxygenation).